Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat

Dual combination therapy with a phosphodiesterase‐5 inhibitor (PDE5i) and endothelin receptor antagonist is recommended for most patients with intermediate‐risk pulmonary arterial hypertension (PAH). The RESPITE and REPLACE studies suggest that switching from a PDE5i to a soluble guanylate cyclase (...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahaghi, Franck F., Balasubramanian, Vijay P., Bourge, Robert C., Burger, Charles D., Chakinala, Murali M., Eggert, Michael S., Elwing, Jean M., Feldman, Jeremy, King, Christopher, Klinger, James R., Mathai, Stephen C., McConnell, John Wesley, Palevsky, Harold I., Restrepo‐Jaramillo, Ricardo, Safdar, Zeenat, Sager, Jeffrey S., Sood, Namita, Sulica, Roxana, White, R. James, Hill, Nicholas S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063960/
https://www.ncbi.nlm.nih.gov/pubmed/35514769
http://dx.doi.org/10.1002/pul2.12055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063960/
https://www.ncbi.nlm.nih.gov/pubmed/35514769
http://dx.doi.org/10.1002/pul2.12055

Ejemplares similares